Compare LGVN & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGVN | CISS |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 1.7M |
| IPO Year | 2021 | 2022 |
| Metric | LGVN | CISS |
|---|---|---|
| Price | $2.70 | $1.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 278.7K | ★ 729.5K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.81 | N/A |
| P/E Ratio | ★ N/A | $0.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.06 |
| 52 Week High | $7.36 | $6.06 |
| Indicator | LGVN | CISS |
|---|---|---|
| Relative Strength Index (RSI) | 79.06 | 45.56 |
| Support Level | $0.61 | $0.76 |
| Resistance Level | $7.30 | $1.89 |
| Average True Range (ATR) | 0.47 | 0.19 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 89.31 | 2.74 |
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.